Search clinical trials for: ONO-4053

Total 12323 results

Ono Pharmaceutical Co. Ltd

Completed

A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053

Healthy Adult Male Subjects

United Kingdom
Ono Pharmaceutical Co. Ltd

Completed

A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers

Healthy Adult Subjects

United Kingdom
Ono Pharmaceutical Co. Ltd

Terminated

A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers

Healthy Adult Subjects

United Kingdom
Gilead Sciences

Completed

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

France, United Kingdom
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Chronic Lymphocytic Leukaemia | Non Hodgkins Lymphoma

United Kingdom, France
Ono Pharmaceutical Co. Ltd

Completed

Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

Austria
Gilead Sciences
German CLL Study Group

Completed

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Sarepta Therapeutics, Inc.
University College, London; Catholic University of the Sacred Heart; University... and other collaborators

Completed

Phase I/II Study of SRP-4053 in DMD Patients

Duchenne Muscular Dystrophy

United Kingdom, United States, France, Italy
Ono Pharmaceutical Co. Ltd

Recruiting

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Primary CNS Lymphoma | Refractory Primary Central Nervous System Lymphoma

United States
Liminal BioSciences Ltd.

Terminated

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Alström Syndrome

United Kingdom
Liminal BioSciences Ltd.

Completed

Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome

Diabetes | Inflammation and Fibrosis

United Kingdom
Liminal BioSciences Ltd.

Completed

A Healthy Volunteer Study of PBI-4050

Fibrosis | Inflammation

United Kingdom
Clavis Pharma

Completed

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Neoplasm Metastasis | Malignant Melanoma

United States, Norway, Sweden
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies

Advanced Malignant Cancer
Sunovion

Terminated

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder (MAD)

Healthy

United States
Liminal BioSciences Ltd.

Terminated

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Type 2 Diabetes Mellitus | Metabolic Syndrome

Canada
Novo Nordisk A/S

Terminated

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Kevin Flanigan
Sarepta Therapeutics, Inc.

Completed

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

Duchenne Muscular Dystrophy

United States
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
Clavis Pharma

Completed

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Advanced Colorectal Cancer

United Kingdom
Hero Institute for Infant Nutrition
Universidad de Murcia; University of Valencia; Universidad de Granada

Completed

Effects of Probiotics in Immune System of Healthy Adults (SETOPROB)

Conditions Influencing Health Status

Spain
Sarepta Therapeutics, Inc.

Terminated

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Belgium, Canada, Spain, United Kingdom, Czechia, Germany, Israel, Bulgaria, France, Italy, Poland, Sweden
Clavis Pharma
Syneos Health; Theradex; CardiaBase; Learn & Confirm

Completed

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Relapsed/Refractory AML

United Kingdom, Spain
Shanghai Haiyan Pharmaceutical Technology Co.,...

Recruiting

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

Solid Tumor

China
Sarepta Therapeutics, Inc.

Active, not recruiting

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)

Duchenne Muscular Dystrophy

United States, Korea, Republic of, Italy, United Kingdom, Canada, Poland, Spain, France, Germany, Belgium, Australia, Czechia, Serbia, Greece, Argentina, Bulgaria, Denmark, Hungary, India, Ireland, Israel, Mexico, Russian Federation, ...
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
Hutchison Medipharma Limited

Unknown

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor, Adult

China
Hutchison Medipharma Limited

Terminated

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor

Australia
Hutchmed

Recruiting

Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

China
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Type 2 Diabetes

Korea, Republic of
Chenland Nutritionals Inc.
KGK Science Inc.

Completed

The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention

Mood

Canada
Oncurious NV
Beat Childhood Cancer

Completed

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)

United States
OPKO Health, Inc.

Terminated

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Adult Growth Hormone Deficiency

Israel
OPKO Health, Inc.
WCCT Global

Completed

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

Growth Hormone Deficiency

United States
PharmAbcine
C&R Research, Inc.

Recruiting

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

Korea, Republic of
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Chronic Pain
Amgen

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Osteoarthritis
Gilead Sciences

Withdrawn

Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
OPKO Health, Inc.

Completed

Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Pediatric Growth Hormone Deficiency

Greece, Hungary, Slovakia
OPKO Health, Inc.

Completed

MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)

Adult Growth Hormone Deficiency

Czechia, Hungary, Israel, Serbia, Slovakia, Slovenia
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
OPKO Health, Inc.

Completed

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Growth Hormone Deficiency (GHD)

United States, Belarus, Greece, Hungary, Russian Federation, Ukraine
Erchonia Corporation

Completed

Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus

Onychomycosis

United States
OPKO Health, Inc.

Active, not recruiting

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Pediatric Growth Hormone Deficiency

Israel, United States, India, Korea, Republic of, Australia, Taiwan, Spain, Argentina, Belarus, Bulgaria, Canada, Colombia, Georgia, Greece, Mexico, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

Hypertension | Chronic Heart Failure
BioInvent International AB
Oxurion

Completed

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Solid Tumors

Denmark
OPKO Health, Inc.
Tel-Aviv Sourasky Medical Center

Completed

MOD-4023 Study in Healthy Male Volunteers

Healthy

Israel

Search clinical trials for: ONO-4053

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations